What is a PD-L1 Test? A PD-L1 test uses a sample of cancerous tumor tissue to measure how much of a protein called PD-L1 is found on the cancer cells. If you have certain types of cancer, PD-L1 testing can check whether you may benefit from a type of cancer treatment called immunotherapy .

Your tumor tested positive for the PD-L1 biomarker. It is important to understand what this means and how it may affect lung cancer treatment. WHAT IS PD-L1? PD-L1 (programmed cell death ligand 1) is a protein that plays a role in the body’s immune system. It can bind to another protein called PD-1. When this happens, the two

May 22, 2017 · A PD-L1 test measures how much PD-L1 a tumor “expresses,” or produces. Tumors that express high amounts of PD-L1 may be more susceptible to checkpoint inhibitors than those that express less. Patients should ask their cancer physicians whether a PD-L1 test is appropriate for them.

A PD-L1 test measures what percentage of cells in a tumor “express” PD-L1. Tumors that express high amounts of PD-L1 (50% or greater) may respond particularly well to checkpoint inhibitors. If you have not had your PD-L1 levels tested, ask your doctor if it is right for you.

Feb 14, 2025 · Programmed death-ligand 1 (PD-L1) is an immune-related biomarker that can be expressed on the surface of many tissue types, including tumor cells. For certain types and stages of cancer, testing for PD-L1 expression may help to identify patients most likely to benefit from treatment with PD-1 inhibitors.

Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti–PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence.

A PD-L1 test uses a sample of cancerous tumor tissue to measure the levels of a protein called PD-L1 is found on the cancer cells. Normally, PD-L1 is found on healthy cells that acts as a “brake” to stop cells in your immune system, called T cells, from attacking healthy cells in …

Therapeutic antibody-mediated blockade of PD-1 or one of its ligands, PD-L1, removes the suppressive effects of PD-L1 on cytotoxic T-cells with restoration of host immunity against the tumour. For some patients, this treatment approach can control or eliminate advanced malignant neoplasms, including metastatic melanoma 1 , which has fostered ...

Feb 6, 2025 · PD-L1, referred to as programmed cell death ligand, is on the outer layer of some normal blood cells, as well as some cancer cells. When PD-1 binds to PD-L1, this puts the brakes on the immune system and can prevent immune cells from attacking and killing cells.

Aug 6, 2020 · Immunohistochemistry assessment of the cell surface protein ligand PD-L1, which is expressed on certain cancer cells. PD-L1 binds with PD-1, a cell surface protein expressed on activated T cells that acts as a checkpoint inhibitor. (Figure 1)